2023 World Conference on Lung Cancer (Posters)-EP13.06. hSSB1 is Elevated and a Potential Target for Therapy in SCLC

EP13.06. hSSB1 is Elevated and a Potential Target for Therapy in SCLC - PDF(Abstract)

Pdf Summary

Small Cell Lung Cancer (SCLC) is a challenging form of lung cancer with a low survival rate. Immunotherapy has only had modest benefits in treating the disease. A protein called hSSB1 has been found to be elevated in SCLC and is also epigenetically elevated in other solid tumors. This suggests that targeting hSSB1 with a therapeutic approach could be a novel treatment option for SCLC. <br /><br />In a study, hSSB1 RNA and protein expression were assessed in SCLC. The study found that hSSB1 was elevated in SCLC patients compared to normal controls. The protein was also detectable in all SCLC cell lines tested. A novel oligonucleotide called DKLS02, which targets hSSB1, was found to inhibit the growth of SCLC cell lines.<br /><br />These findings suggest that targeting hSSB1 with oligonucleotides like DKLS02 could be a potential therapy for SCLC. This approach represents a new and promising therapeutic strategy for treating this challenging form of lung cancer. <br /><br />Overall, SCLC remains a major therapeutic challenge, but the discovery of elevated hSSB1 in the disease and the potential for targeted therapy using novel oligonucleotides provide hope for improved treatment options in the future.

Asset Subtitle

Amila Suraweera

Meta Tag

Speaker Amila Suraweera

Topic SCLC & Neuroendocrine Tumors: Preclinical

Keywords

Small Cell Lung Cancer

SCLC

lung cancer

hSSB1

epigenetics

solid tumors

oligonucleotide

DKLS02

targeted therapy

treatment options